Radiotherapy using IMRT boosts after hyperbaric oxygen therapy with chemotherapy for glioblastoma
| Autor: | Hajime Imada, Kyosuke Tomura, Yukunori Korogi, Junkoh Yamamoto, Takayuki Ohguri, Katsuya Yahara, Hiroki Udono, Shigeru Nishizawa, Toshihiro Onoda |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Adult Male Health Toxicology and Mutagenesis medicine.medical_treatment Antineoplastic Agents Disease-Free Survival 03 medical and health sciences Young Adult 0302 clinical medicine Hyperbaric oxygen Edema medicine Regular Paper Humans Radiology Nuclear Medicine and imaging In patient Conformal radiation Aged Aged 80 and over Chemotherapy Hyperbaric Oxygenation Radiation business.industry Brain Neoplasms glioblastoma Middle Aged medicine.disease intensity-modulated radiotherapy Radiation therapy 030104 developmental biology 030220 oncology & carcinogenesis hyperbaric oxygen Disease Progression Combined therapy Female Radiotherapy Intensity-Modulated medicine.symptom radiosensitization Nuclear medicine business high-grade glioma Glioblastoma |
| Zdroj: | Journal of Radiation Research |
| ISSN: | 1349-9157 0449-3060 |
| Popis: | The purpose of this study was to evaluate the feasibility and efficacy of radiotherapy (RT) using intensity-modulated radiotherapy (IMRT) boosts after hyperbaric oxygen (HBO) therapy with chemotherapy in patients with glioblastoma. Twenty-four patients with glioblastoma were treated with the combined therapy, which was RT using IMRT boosts after HBO with chemotherapy, and were retrospectively analyzed. The RT protocol was as follows: first, 3D conformal RT [40 Gy/20 fractions (fr)] was delivered to the gross tumor volume (GTV) and the surrounding edema, including an additional 1.5–2.0 cm. The IMRT boost doses were then continuously delivered to the GTV plus 5 mm (28 Gy/8 fr) and the surrounding edema (16 Gy/8 fr). Each IMRT boost session was performed immediately after HBO to achieve radiosensitization. The planned RT dose was completed in all patients, while HBO therapy was terminated in one patient (4%) due to Grade 2 aural pain. The toxicities were mild, no non-hematological toxicity of Grade 3–5 was observed. The 2-year overall survival (OS) and progression-free survival rates in all patients were 46.5% and 35.4%, respectively. The median OS time was 22.1 months. In conclusion, the combined therapy of RT using IMRT boosts after HBO with chemotherapy was a feasible and promising treatment modality for patients with glioblastoma. The results justify further evaluation to clarify the benefits of this therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|